Acquired
Immunodeficiency Syndrome (AIDS) is an immunodeficiency state caused by an
infection with the human immunodeficiency virus, HIV. There are several drugs
being studied for HIV, AIDS, and AIDS-related illnesses. Listed above are some
antiviral, cytokine, immunomodulating drugs, and vaccines currently undergoing
clinical trials.
|
AIDS
|
|
ACT (activated cellular therapy)
|
other
|
II
|
Neoprobe
|
|
Amprenavir (Agenerase)
1 and indinavir (Crixivan)
1
|
protease inhibitor combination
|
II
|
Vertex Pharmaceuticals/Kissei Pharmaceutical
|
|
Amprenavir (Agenerase) 1 and nelfinavir (Viracept) 1
|
protease inhibitor combination
|
II
|
Vertex Pharmaceuticals/Kissei Pharmaceutical
|
|
Amprenavir (Agenerase) 1 and saquinavir (Fortovase)
1
|
protease inhibitor combination
|
II
|
Vertex Pharmaceuticals /Kissei Pharmaceutical
|
|
Amprenavir (Agenerase),
1
zidovudine (Retrovir), 1 and lamivudine (Epivir)
1
|
Second generation HIV protease inhibitor combination
|
III
|
Vertex Pharmaceuticals /GlaxoWellcome
|
|
BMS-234475/CGP-61755
|
nd
2
|
I
|
Bristol-Myers Squibb
|
|
Cytolin
|
nontoxid AIDS monoclonal antibody
|
I/II
|
CytoDyn Inc.
|
|
MDX-240
|
virus-specific bispecific antibody
|
I/II
|
Medarex Inc.
|
|
Trichosanthin (GLQ223; Compound Q)
|
antiviral
|
II
|
Genelabs Technologies
|
|
Zidovudine
1/Didanosine
1 (Scriptene)
|
heterodimer
|
II
|
IVX Bioscience Inc./SS Pharmaceuticals
|
|
Cachexia
|
|
Testosterone
1
|
anabolic steroid
|
II
|
TheraTech
|
|
CMV infection
|
|
Benzimidavir (1263W94)
|
CMV-DNA inhibitor
|
II
|
GlaxoWellcome
|
|
CMV retinitis
|
|
GEM 132 intravenous
|
hybrid antisense oligonucleotide
|
II
|
Hybridon
|
|
GEM 132 intravitreal
|
hybrid antisense oligonucleotide
|
II
|
Hybridon
|
|
GW275175
|
CMV-DNA maturation inhibitor
|
I
|
GlaxoWellcome
|
|
ISIS 13312
|
second generation antisense compound
|
I
|
Isis Pharmaceuticals
|
|
Valganciclovir (Cymeval)
|
antiviral
|
III
|
Hoffman-LaRoche
|
|
Dementia
|
|
Memantine
|
NMDA receptor antagonist/neuroprotective agent
|
II
|
Neurobiological Technologies
|
|
Diarrhea
|
|
DEHOP (diethylhomospermine)
|
polyamine analogue /antidiarrheal agent
|
II
|
SunPharm Corp.
|
|
Letrazurile
|
nd
2
|
II
|
Janssen Pharmaceutica
|
|
Synsorb CD (due to Clostridium difficile)
|
gastrointestinal
|
II
|
Synsorb Biotech
|
|
Genital herpes
|
|
Cidofovir gel (Forvade)
|
antiviral
|
I/II
|
Gilead Sciences
|
|
HIV infection
|
|
ABT 378
|
protease inhibitor combination
|
II
|
Abbott Laboratories
|
|
Aldesleukin (Proleukin) 1 interleukin-2 (IL-2)
|
interleukin
|
III
|
Chiron
|
|
Ampligen
|
nucleic acid
|
II
|
HemispheRx Biopharma Inc.
|
|
BCH 10652
|
reverse transcriptase inhibitor
|
II
|
BioChem Pharma
|
|
BMS 232632
|
protease azapeptide inhibitor
|
I
|
Bristol-Myers Squibb
|
|
BMS-234475
|
second generation protease inhibitor
|
II
|
Bristol-Myers Squibb
|
|
Calanolide A
|
NNRTI
3
|
I/II
|
Sarawak MediChem
|
|
CS-92
|
NRTI
4
|
I/II
|
Triangle Pharmaceuticals
|
|
CTL (adoptive immunotherapy)
|
gene therapy
|
I
|
Targeted Genetics
|
|
DAPD
|
purine dioxolane nucleoside
|
I
|
Triangle Pharmaceuticals
|
|
DMP-266
|
NNRTI
3
|
III
|
DuPont Merck
|
|
DMP-450
|
second generation protease inhibitor
|
I/II
|
Triangle Pharmaceuticals
|
|
HIV Therapeutic
|
nd
2
|
I
|
United Biomedical
|
|
HGP-30 and sargramostim
1
|
nd
2
|
I
|
Cel-Sci Corp./Immunex Corp.
|
|
HIV-IT
|
nd
2
|
II
|
Chiron Viagene
|
|
Indinavir (Crixivan in NanoCrystal formulation)
|
protease inhibitor
|
II
|
NanoSystems LLC/Merck and Co. Inc.
|
|
Interferon alfa-n3 Alferon N
1 injection
|
nd
2
|
III
|
Interferon Sciences
|
|
Interleukin-10 (Tenovil)
|
immunoregulatory agent
|
I
|
Schering-Plough Corp.
|
|
Iodenosine (f-ddA)
|
purine-based reverse transcriptase inhibitor
|
II
|
NCI US Bioscience
|
|
ISIS 5320
|
nd
2
|
I
|
Isis Pharmaceuticals, Inc.
|
|
Multikine
|
immunotherapeutic agent
|
I
|
Cel-Sci Corp.
|
|
n-docosanol (Lidakol)
|
broad-spectrum antiviral
|
II
|
Avanir Pharmaceuticals
|
|
Nevirapine (Viramune), 1 zidovudine (Retrovir),
1 and
didanosine (Videx)
1
|
protease inhibitor /reverse transcriptase
inhibitor /nucleoside analogue
|
III
|
Boehringer Ingelheim Pharmaceuticals/Roxane Laboratories
|
|
NIBA
|
nd
2
|
I
|
Octamer
|
|
PMPA (tenofovir dipivoxil)
|
nucleotide inhibitor
|
II
|
Gilead Sciences
|
|
Pro 367
|
radiolabeled universal antigen binding agent
|
I/II
|
Progenics
|
|
Pro 542
|
recombinant universal antigen binding agent; HIV
attachment inhibitor
|
I/II
|
Progenics
|
|
Pro 2000 gel
|
antiviral agent/microbicide
|
I NIAID trial
|
Procept
|
|
Procaine HCl (Anticort) 1
|
nd
2
|
II
|
Steroidogenesis Inhibitors International
|
|
Rev M10pol AS (HSC-1P)
|
nd
2
|
I/II
|
Novartis
|
|
Saquinavir mesylate (Fortovase)
1 in
combination with ritonavir (Norvir)
1 and either zidovudine (Retrovir)
1 or
lamivudine (Epivir)
1
|
protease inhibitor combination or protease
inhibitor/reverse transcriptase inhibitor combination
|
III
|
Hoffmann-LaRoche
|
|
Sargramostim
1 (granulocyte macrophage colony
stimulating factor; GM- CSF; Leukine)
|
colony stimulating factor
|
III
|
Immunex
|
|
Savvy
|
vaginal gel microbicide and spermicide
|
I/II
|
Biosyn
|
|
TAT antagonist
|
antiviral
|
I/II
|
Hoffman-LaRoche
|
|
T-cell gene therapy
|
gene therapy
|
II
|
Cell Genesys
|
|
Thymopentin (Timunox)
|
immunomodulator
|
III
|
Immunobiology Research Institute
|
|
Tipranavir
|
nonpeptidic HIV protease inhibitor
|
II
|
Pharmacia and Upjohn
|
|
Tirilazed Mesylate
|
protease inhibitor
|
I/II
|
GlaxoWellcome
|
|
Tucaresol (immuno-potentiator)
|
immunomodulator / immunopotentiator
|
II
|
GlaxoWellcome
|
|
Tumor necrosis factor (TNF)
|
antiviral
|
I
|
Immunex
|
|
Zintevir (AR177)
|
integrase inhibitor
|
I/II
|
Aronex
|
|
HIV infection and AIDS
|
|
Abavca/Perthon
|
plant derivative
|
I/II
|
Advanced Plant Pharmaceuticals
|
|
Abacavir sulfate (Ziagen)
1 and
amprenavir (Agenerase)
1
|
nucleoside analogue/protease inhibitor
|
III
|
Vertex Pharmaceuticals / GlaxoWellcome
|
|
AG 1549
|
NNRTI
3
|
II
|
Agouron Pharmaceuticals
|
|
Atevirdine mesylate
|
NNRTI
3
|
II/III
|
Pharmacia and Upjohn
|
|
Efavirenz (Sustiva),1 lamivudine (Epivir),
1 and
zidovudine (Retrovir)
1
|
NNRTI
3 /nucleoside analogue/NRTI
4
|
III
|
DuPont Pharmaceuticals
|
|
FTC, emtricitabine (Coviracil)
|
nucleoside analogue
|
II/III
|
Triangle Pharmaceuticals
|
|
HMR 4004
|
CD4-zeta gene-modified T-lymphocytes
|
II
|
Hoechst-Marion Roussel
|
|
Inactivin (HE 200)
|
cellular energy regulators
|
I
|
Hollis-Eden Pharmaceuticals
|
|
Interferon alfa-n3 (Alferon LDO)
1
|
cytokine
|
I/II
|
Interferon Sciences
|
|
MKC-442
|
NNRTI
3
|
III
|
Triangle Pharmaceuticals
|
|
MPL
|
nd
2
|
I/II
|
Ribi ImmunoChem Research
|
|
Probucol (Panavir)
|
antiviral
|
II
|
Vyrex
|
|
PNU-140690
|
protease inhibitor
|
II
|
Pharmacia and Upjohn
|
|
T-20
|
fusion inhibitor
|
II
|
MiniMed/Trimeris
|
|
Zidovudine (Aztec) controlled-release
|
antiviral
|
III
|
Verex
|
|
HIV wasting
|
|
Androderm
1
|
testosterone replacement
|
III
|
SmithKline Beecham
|
|
Dihydrotestosterone gel (Androgel DHT)
|
steroid
|
II
|
Unimed
|
|
Oxandrolone (Oxandrin) gel
|
steroid
|
III
|
Bio-Technology
|
|
Thalidomide (Thalomid)1
|
TNF-alpha selective inhibitor
|
II
|
Celgene
|
|
Hodgkin’s
lymphoma
|
|
Aldesleukin (Proleukin ; IL-2)
1
|
interleukin
|
II (NCI trial)
|
Chiron
|
|
Kaposi’s sarcoma
|
|
9-aminocamptothecin
|
topoisomerase I inhibitor
|
II (NCI trial)
|
NCI
|
|
9-cis-retinoic acid
|
nd
2
|
I/II (NCI trial)
|
Ligand Pharmaceuticals
|
|
Alitretinoin (Panretin) oral
|
retinoic acid
|
II/III
|
Ligand Pharmaceuticals
|
|
Cidofovir
|
antiviral
|
I/II
|
Gilead Sciences
|
|
COL-3
|
nd
2
|
I (NCI trial)
|
NCI
|
|
Interleukin-12
|
interleukin
|
I/II (NCI trial)
|
NCI
|
|
LIDAKOL (n-docosanol)
|
nd
2
|
II
|
LIDAK Pharmaceuticals
|
|
Panretin and interferon
|
nd
2
|
I/II
|
Ligand Pharmaceuticals
|
|
Phenylhydrazone
|
antiviral
|
I
|
Dekk-Tec
|
|
SU5416
|
angiogenesis inhibitor
|
I/II
|
SUGEN
|
|
Thalidomide
1
|
cytokine-selective inhibitor
|
II
|
Andrulis
|
|
Thalidomide
1
|
nd
2
|
II (NCI trial)
|
NCI
|
|
Tretinoin (Atragen)
|
liposomal all-transretinoic acid
|
II completed
|
Aronex Pharmaceuticals
|
|
Virulizin
|
macrophage activator
|
I/II
|
Imutec Pharma
|
|
Lymphomas
|
|
Virulizin
|
macrophage activator
|
I/II
|
Imutec Pharma
|
|
Mycobacterial
infection
|
|
Amikasin (MiKasome)
|
nd
2
|
II
|
NeXstar Pharmaceuticals
|
|
Mycobacterial
avium complex
|
|
Rifalazil (PA-1648)
|
rifampin derivative
|
II
|
PathoGenesis
|
|
Non-hodgkin’s
lymphoma
|
|
506478 prodrug of guanine
|
arabinoside
|
I
|
GlaxoWellcome
|
|
DEHOP (diethylhomospermine)
|
polyamine analogue/antidiarrheal agent
|
II
|
SunPharm Corp.
|
|
G3139
|
antisense compound
|
I/II
|
Genta
|
|
Gallium nitrate
|
nd
2
|
II (NCI trial)
|
NCI
|
|
Humanized Mab LL2 (LymphoCide)
|
nd
2
|
I/II
|
Immunomedics
|
|
Pentostatin (Nipent)
|
nd
2
|
II
|
SuperGen
|
|
Tretinoin (Atragen)
|
liposomal all-transretinoic acid
|
II
|
Aronex Pharmaceuticals
|
|
Progressive
multifocal leukoencephalopathy (PML)
|
|
Topotecan
|
nd
2
|
II
|
SmithKline Beecham
|
|
Vaccines
|
|
AIDS vaccine
|
multi-envelope HIV vaccine component
|
I
|
St. Jude Children’s Research Hospital
|
|
ALVAC -120TMG (VCP205)
|
vaccine
|
II
|
Pasteur Merieux Connaught
|
|
Genevax-HIV
|
vaccine
|
I
|
Wyeth-Lederle
|
|
gp120 (Aidsvax)
|
vaccine
|
III
|
VaxGen
|
|
HGP-30 W
|
HIV vaccine
|
II
|
Cel-Sci Corp.
|
|
HIV vaccine
|
vaccine
|
II
|
Pasteur Merieux Connaught/Chiron Corp.
|
|
HIV-1 peptide vaccine
|
vaccine
|
I (NCI trial)
|
NCI
|
|
Remune
|
vaccine
|
III IV
|
Immune Response/Agouron Pharm
|
|
TBC-3B
|
vaccine
|
I AIDS
|
Therion Biologics
|
|
Xerostomia
|
|
Interferon alpha (Veldona Lozenge)
|
natural human interferon-alpha
|
II
|
Amarillo Biosciences
|
1
Approved for other indications; refer to individual
monographs.
AIDS Zone 
